Low
暂无分享,去创建一个
[1] B. Whipp,et al. The role of nitrogen oxides in human adaptation to hypoxia , 2011, Scientific reports.
[2] M. Feelisch. The use of nitric oxide donors in pharmacological studies , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.
[3] S. Rice,et al. Cephalosporin-3'-diazeniumdiolates: targeted NO-donor prodrugs for dispersing bacterial biofilms. , 2012, Angewandte Chemie.
[4] J. Gustafson,et al. Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.
[5] I. Chopra,et al. Increased mutability of Pseudomonas aeruginosa in biofilms. , 2008, The Journal of antimicrobial chemotherapy.
[6] T. Scheike,et al. Polymorphonuclear Leukocytes Restrict Growth of Pseudomonas aeruginosa in the Lungs of Cystic Fibrosis Patients , 2014, Infection and Immunity.
[7] P. Nielsen,et al. True Microbiota Involved in Chronic Lung Infection of Cystic Fibrosis Patients Found by Culturing and 16S rRNA Gene Analysis , 2011, Journal of Clinical Microbiology.
[8] Matthew R. Parsek,et al. Pseudomonas aeruginosa Rugose Small-Colony Variants Have Adaptations That Likely Promote Persistence in the Cystic Fibrosis Lung , 2009, Journal of bacteriology.
[9] Jeremy S. Webb,et al. Nitric oxide‐mediated dispersal in single‐ and multi‐species biofilms of clinically and industrially relevant microorganisms , 2009, Microbial biotechnology.
[10] D. Laskin,et al. The toxicology of inhaled nitric oxide. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.
[11] N. Høiby,et al. Eradication of early Pseudomonas aeruginosa infection. , 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[12] Xueji Zhang,et al. Novel Calibration Method for Nitric Oxide Microsensors by Stoichiometrical Generation of Nitric Oxide from SNAP , 2000 .
[13] J. Heesemann,et al. Specific and Rapid Detection by Fluorescent In Situ Hybridization of Bacteria in Clinical Samples Obtained from Cystic Fibrosis Patients , 2000, Journal of Clinical Microbiology.
[14] Philip S. Stewart,et al. Contributions of Antibiotic Penetration, Oxygen Limitation, and Low Metabolic Activity to Tolerance of Pseudomonas aeruginosa Biofilms to Ciprofloxacin and Tobramycin , 2003, Antimicrobial Agents and Chemotherapy.
[15] P. Williams,et al. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. , 2007, Microbiology.
[16] Thomas Bjarnsholt,et al. Towards diagnostic guidelines for biofilm-associated infections. , 2012, FEMS immunology and medical microbiology.
[17] B. Ersbøll,et al. Quantification of biofilm structures by the novel computer program COMSTAT. , 2000, Microbiology.
[18] D. Hassett,et al. Involvement of Nitric Oxide in Biofilm Dispersal of Pseudomonas aeruginosa , 2006, Journal of bacteriology.
[19] Chris C. Miller,et al. A phase I clinical study of inhaled nitric oxide in healthy adults. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[20] Zbigniew Lewandowski,et al. Effects of biofilm structures on oxygen distribution and mass transport , 1994, Biotechnology and bioengineering.
[21] R. Amann,et al. Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed microbial populations , 1990, Applied and environmental microbiology.
[22] D. Hassett,et al. Nitric Oxide Signaling in Pseudomonas aeruginosa Biofilms Mediates Phosphodiesterase Activity, Decreased Cyclic Di-GMP Levels, and Enhanced Dispersal , 2009, Journal of bacteriology.
[23] Garth D Ehrlich,et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. , 2006, JAMA.
[24] M. Givskov,et al. The immune system vs. Pseudomonas aeruginosa biofilms. , 2010, FEMS immunology and medical microbiology.
[25] Lucas Smith,et al. Phenotypic Characterization of Clonal and Nonclonal Pseudomonas aeruginosa Strains Isolated from Lungs of Adults with Cystic Fibrosis , 2007, Journal of Clinical Microbiology.
[26] B. Rubin,et al. Nitric oxide metabolites in cystic fibrosis lung disease , 1998, Archives of disease in childhood.
[27] N. Bryan,et al. Cellular targets and mechanisms of nitros(yl)ation: An insight into their nature and kinetics in vivo , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[28] A. Oliver,et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[29] S. Zeger,et al. Longitudinal data analysis using generalized linear models , 1986 .
[30] L. Hoffman,et al. Reducing bias in bacterial community analysis of lower respiratory infections , 2012, The ISME Journal.
[31] Samuel I. Miller,et al. The bacterial second messenger c‐di‐GMP: mechanisms of signalling , 2011, Cellular microbiology.
[32] S. Aaron,et al. Single and Combination Antibiotic Susceptibilities of Planktonic, Adherent, and Biofilm-Grown Pseudomonas aeruginosa Isolates Cultured from Sputa of Adults with Cystic Fibrosis , 2002, Journal of Clinical Microbiology.
[33] Li Zhang,et al. The exopolysaccharide Psl-eDNA interaction enables the formation of a biofilm skeleton in Pseudomonas aeruginosa. , 2015, Environmental microbiology reports.
[34] S. Kjelleberg,et al. Microbial biofilm formation: a need to act , 2014, Journal of internal medicine.
[35] N. Bryan,et al. Bound NO in human red blood cells: fact or artifact? , 2004, Nitric oxide : biology and chemistry.
[36] M. Kühl,et al. Physiological levels of nitrate support anoxic growth by denitrification of Pseudomonas aeruginosa at growth rates reported in cystic fibrosis lungs and sputum , 2014, Front. Microbiol..
[37] S. Aaron,et al. Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis , 2004, European Respiratory Journal.
[38] A. Gieseke,et al. Fluorescence "in situ" hybridization for the detection of biofilm in the middle ear and upper respiratory tract mucosa. , 2009, Methods in molecular biology.
[39] Michael J. MacCoss,et al. Aminoglycoside antibiotics induce bacterial biofilm formation , 2005, Nature.
[40] S. Collins,et al. Role of Mutation in Pseudomonas aeruginosa Biofilm Development , 2009, PloS one.
[41] L. Nordvall,et al. Oral bacteria--the missing link to ambiguous findings of exhaled nitrogen oxides in cystic fibrosis. , 2009, Respiratory medicine.
[42] C. K. van der Ent,et al. Nitric oxide in cystic fibrosis. , 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[43] S. Lory,et al. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[44] A. Vanderkelen,et al. Direct detection and identification of Pseudomonas aeruginosa in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane lipoprotein genes, oprI and oprL , 1997, Journal of clinical microbiology.
[45] A. Quittner,et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. , 2000, Journal of pediatric psychology.
[46] T. Tolker-Nielsen,et al. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB‐oprM genes , 2008, Molecular microbiology.
[47] J. Costerton,et al. Pseudomonas aeruginosa biofilm as a diffusion barrier to piperacillin , 1992, Antimicrobial Agents and Chemotherapy.
[48] B. McCollister,et al. Nitric Oxide Protects Bacteria from Aminoglycosides by Blocking the Energy-Dependent Phases of Drug Uptake , 2011, Antimicrobial Agents and Chemotherapy.
[49] M. Schoenfisch,et al. Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. , 2009, Biomaterials.
[50] F. Ratjen,et al. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[51] H. Ceri,et al. The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms , 1999, Journal of Clinical Microbiology.
[52] L. Hoffman,et al. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience , 2012, Thorax.
[53] W. Zapol,et al. Brief Periods of Nitric Oxide Inhalation Protect against Myocardial Ischemia–Reperfusion Injury , 2008, Anesthesiology.
[54] M. Schoenfisch,et al. Bactericidal efficacy of nitric oxide-releasing silica nanoparticles. , 2008, ACS nano.
[55] S. Molin,et al. The clinical impact of bacterial biofilms , 2011, International Journal of Oral Science.
[56] A. Denicola,et al. Acceleration of nitric oxide autoxidation and nitrosation by membranes , 2007, IUBMB life.
[57] Chris C. Miller,et al. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. , 2009, Nitric oxide : biology and chemistry.
[58] Pradeep K. Singh,et al. Cystic Fibrosis Sputum Supports Growth and Cues Key Aspects of Pseudomonas aeruginosa Physiology , 2005, Journal of bacteriology.
[59] Chris C. Miller,et al. Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study , 2016, Infection.
[60] Diane McDougald,et al. Should we stay or should we go: mechanisms and ecological consequences for biofilm dispersal , 2011, Nature Reviews Microbiology.
[61] A. Prince. Biofilms, antimicrobial resistance, and airway infection. , 2002, The New England journal of medicine.
[62] Gerald B. Pier,et al. Lung Infections Associated with Cystic Fibrosis , 2002, Clinical Microbiology Reviews.
[63] T. McMahon,et al. Inhaled nitric oxide therapy increases blood nitrite, nitrate, and s-nitrosohemoglobin concentrations in infants with pulmonary hypertension. , 2012, The Journal of pediatrics.